AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Candel Therapeutics, Inc. Director's Dealing 2023

Nov 30, 2023

33336_dirs_2023-11-30_89abfa1c-06d7-4465-bc6b-1a118d912560.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Candel Therapeutics, Inc. (CADL)
CIK: 0001841387
Period of Report: 2023-11-28

Reporting Person: Amello Jason (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-11-28	Common Stock	F	20153	$0.90	Disposed	202009	Direct

Footnotes

F1: These shares were withheld by the Issuer to satisfy tax withholding obligations associated with the vesting and settlement of restricted stock units.